ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is giving an update on the usage of the “at the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out a “at the market” equity offering program under which Acasti may issue as well as sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January twenty seven, 2021, Acasti granted an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares were offered at prevailing market rates averaging US$1.0747 a share. No securities were marketed throughout the facilities of the TSXV or, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and can provide the Company with more freedom in its continuous review process to explore as well as evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications using OM3 greasy acids delivered both as free fatty acids and bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical evidence of efficacy and safety for lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being created for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release which aren’t statements of current or historical truth constitute “forward looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking statements include known and unknown risks, uncertainties, and other unknown elements that can cause the actual outcomes of Acasti to be materially different from historical success or as a result of any later results expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, people are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be uncertain and forward-looking. People are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking assertions in that press release include, but are not confined to, info or statements concerning Acasti’s strategy, succeeding operations and the review of its of strategic alternatives.
The forward-looking statements contained in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area contained in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor section of Acasti’s site at www.acastipharma.com. Many forward-looking claims in this press release are produced as of the particular date of this particular press release.
ACST Stock – Acasti does not undertake to upgrade any such forward-looking statements whether as a direct result of information that is brand new , future events or even otherwise, except as needed by law. The forward looking assertions contained herein are also subject generally to assumptions and risks as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage